Atara Biotherapeutics
ATRA
74 hedge funds and large institutions have $493M invested in Atara Biotherapeutics in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 44 increasing their positions, 8 reducing their positions, and 6 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 8
228% more capital inflows, than outflows
Capital inflows: $55.3M | Capital outflows: $16.9M
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
6.77% more ownership
Funds ownership: 68.88% → 75.65% (+6.8%)
4% more funds holding
Funds holding: 71 → 74 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.8M |
| 2 |
Slate Path Capital
New York
|
+$8.06M |
| 3 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.74M |
| 4 |
BM
Bridger Management
New York
|
+$5.31M |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$11.5M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$1.22M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$1.21M |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.05M |
| 5 |
Eagle Asset Management
St Petersburg,
Florida
|
-$1.03M |
ATRA Hedge Fund Activity: Q2 2016 in Review
74 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2016, worth a combined $493M — up 31% from $377M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATRA positions and 6 closed out — a net gain of 3 holders — while 44 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.8M. The largest seller was Visium Asset Management, exiting entirely with an estimated $11.5M sold.
- 74 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2016, up from 71 in Q1 2016.
- Funds reported $493M of Atara Biotherapeutics stock for Q2 2016, up 31% quarter-over-quarter.
- 9 funds opened new Atara Biotherapeutics positions in Q2 2016 and 6 closed out, a net change of +3 holders.
- The largest Atara Biotherapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $13.8M added.
- The largest Atara Biotherapeutics seller in Q2 2016 was Visium Asset Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2016.